Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.